SCHEMBL25928265

SCHEMBL25928265

CCCCCCC(CCCCC)CN1CCC2(CC1)CCN(C(=O)C(CCCC)CCCCC)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 1/20 0.42
CYP2D6 P10635 10/20 0.40
CA2 P00918 1/20 0.38
TSHR P16473 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.34
CCKBR P32239 1/20 0.34
USP2 O75604 1/20 0.33
CYP2C9 P11712 1/20 0.33
CHRM2 P08172 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
OPRM1 P35372 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23696029 1.00 OPRL1 (0.42) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL23945292 0.91 OPRL1 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL25707614 0.91 OPRL1 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL25884453 0.90 CYP2D6 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL25109469 0.90 CYP2D6 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL25829570 0.90 CYP2D6 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL25480257 0.90 CYP2D6 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL26405347 0.90 CYP2D6 (0.38) OPRL1CYP2D6CA2TSHRLMNA
SCHEMBL23806518 0.89 CYP2D6 (0.42) OPRL1CYP2D6TSHRLMNAALDH1A1
SCHEMBL25728789 0.88 CYP2D6 (0.36) OPRL1CYP2D6CA2TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 OPRL1 2347/4885CYP2D6 3599/4885CA2 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.